Natera

Natera is owned by LifeLabs. LifeLabs has a direct presence in 3 countries.

LifeLabs has 4 subsidiaries including Centogene, Hemostasis Reference Laboratory and NanoString Technologies.

They are in:

• Biotechnology60%
• Healthcare40%

View the org chart displaying its 34 main executives

Most searched biographies at Natera

• Steve Chapman, Chief Executive Officer and Director
• Gail Marcus, Director
• Rowan Chapman, Director

Popular executive movements at Natera

• Solomon Moshkevich, who was General Manager, Oncology, is promoted to President of Clinical Diagnostics  (posted on September 19 2023).
• John Fesko, who was Chief Business Officer, is promoted to President and Chief Business Officer  (posted on September 19 2023).
• Alexey Aleshin, who was General Manager, Early Cancer Detection, is promoted to General Manager of Oncology and Early Cancer Detection  (posted on September 19 2023).

Create your alert
to follow the executive moves at Natera.

LifeLabs has 2,282 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Natera

• Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
• Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
• Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
• Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
• Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
• Natera Reports First Quarter 2023 Financial Results
• Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
• Natera Announces First Quarter 2023 Earnings Conference Call
• Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
• New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
• View more press releases Close

Social media about Natera

• Natera on Wikipedia, Google News & Yahoo Finance
• Natera on LinkedIn, Twitter & YouTube

Contact by email its executives including Steve Chapman

Call Natera at +1 650...

View the org chart

Register to receive your alert

Report an error